In the quest to outshine the broader market, stock pickers diligently seek out stocks with the potential for superior performance. Making the right choices can significantly elevate your wealth.
The closing price of Atara Biotherapeutics Inc (NASDAQ: ATRA) was $5.88 for the day, down -56.99% from the previous closing price of $13.67. In other words, the price has decreased by -$56.99 from its previous closing price. On the day, 4.6 million shares were traded. ATRA stock price reached its highest trading level at $6.51 during the session, while it also had its lowest trading level at $5.58.
Ratios:
Our analysis of ATRA’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 1.02 and its Current Ratio is at 1.02.
Upgrades & Downgrades
In the most recent recommendation for the company, Mizuho on November 09, 2023, Downgraded its rating to Neutral and sets its target price to $1 from $31 previously.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Jan 12 ’26 when Panacea Innovation Ltd bought 40,000 shares for $5.88 per share.
Nguyen AnhCo sold 2,915 shares of ATRA for $38,437 on Nov 17 ’25. The President and CEO now owns 64,974 shares after completing the transaction at $13.19 per share. On Nov 17 ’25, another insider, Grant-Huerta Yanina, who serves as the Chief Accounting Officer of the company, sold 1,804 shares for $13.19 each. As a result, the insider received 23,788 and left with 33,454 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ATRA now has a Market Capitalization of 42396184 and an Enterprise Value of 45642180. As of this moment, Atara’s Price-to-Earnings (P/E) ratio for their current fiscal year is 2.68, and their Forward P/E ratio for the next fiscal year is 14.58. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 0.32. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.28. Its current Enterprise Value per Revenue stands at 0.3 whereas that against EBITDA is 1.018.
Stock Price History:
The Beta on a monthly basis for ATRA is -0.42, which has changed by 0.110479236 over the last 52 weeks, in comparison to a change of 0.19226205 over the same period for the S&P500. Over the past 52 weeks, ATRA has reached a high of $19.15, while it has fallen to a 52-week low of $5.01. The 50-Day Moving Average of the stock is -60.39%, while the 200-Day Moving Average is calculated to be -48.07%.
Shares Statistics:
ATRA traded an average of 92.47K shares per day over the past three months and 233170 shares per day over the past ten days. A total of 7.21M shares are outstanding, with a floating share count of 4.16M. Insiders hold about 42.24% of the company’s shares, while institutions hold 26.29% stake in the company. Shares short for ATRA as of 1767139200 were 169201 with a Short Ratio of 1.83, compared to 1764288000 on 164713. Therefore, it implies a Short% of Shares Outstanding of 169201 and a Short% of Float of 2.8399997999999997.
Earnings Estimates
The stock of Atara Biotherapeutics Inc (ATRA) is currently in the spotlight, with 4.0 analysts actively rating and assessing its market standing.The consensus estimate for the next quarter is $2.46, with high estimates of $2.46 and low estimates of $2.46.
Analysts are recommending an EPS of between $4.48 and -$3.5 for the fiscal current year, implying an average EPS of $1.29. EPS for the following year is $0.45, with 4.0 analysts recommending between $1.99 and -$0.72.
Revenue Estimates
For the next quarter, 4 analysts are estimating revenue of $42.75M. There is a high estimate of $43.09M for the next quarter, whereas the lowest estimate is $42.4M.
A total of 3 analysts have provided revenue estimates for ATRA’s current fiscal year. The highest revenue estimate was $122.2M, while the lowest revenue estimate was $119.18M, resulting in an average revenue estimate of $120.33M. In the same quarter a year ago, actual revenue was $128.94MBased on 5 analysts’ estimates, the company’s revenue will be $53.95M in the next fiscal year. The high estimate is $79M and the low estimate is $32M.
